Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTL Artelo Biosciences	$9.35 -1.9%	$11.56	$4.92 ▼ $28.60	$6.71M	1.36	125,502 shs	23,701 shs
MDCX Medicus Pharma	$2.22 -9.4%	$2.67	$1.80 ▼ $8.94	$33.25M	N/A	411,232 shs	590,547 shs
MURA Mural Oncology	$2.08 +0.5%	$2.27	$0.95 ▼ $4.74	$35.86M	3	551,494 shs	435,374 shs
RNTX Rein Therapeutics	$1.27 +12.4%	$1.37	$1.04 ▼ $4.40	$26.33M	1.31	68,409 shs	39,885 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTL Artelo Biosciences	-1.89%	-6.69%	-36.57%	+63.57%	+16.30%
MDCX Medicus Pharma	-9.39%	+13.27%	-27.21%	-69.55%	+221,999,900.00%
MURA Mural Oncology	+0.48%	+18.18%	-16.13%	-24.36%	-36.78%
RNTX Rein Therapeutics	+12.39%	+6.37%	-18.06%	-38.05%	+126,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARTL Artelo Biosciences	3.1576 of 5 stars	3.8	5.0	0.0	0.0	2.5	0.0	0.6
MDCX Medicus Pharma	1.9406 of 5 stars	3.8	0.0	0.0	0.0	2.2	0.8	0.0
MURA Mural Oncology	3.0017 of 5 stars	3.3	3.0	0.0	0.0	1.8	2.5	1.3
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARTL Artelo Biosciences	3.60	Strong Buy	$24.00	156.68% Upside
MDCX Medicus Pharma	3.50	Strong Buy	$23.50	958.56% Upside
MURA Mural Oncology	2.50	Moderate Buy	$12.00	476.92% Upside
RNTX Rein Therapeutics	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest ARTL, MURA, RNTX, and MDCX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
8/19/2025	RNTX Rein Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/18/2025	ARTL Artelo Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
8/13/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
8/4/2025	ARTL Artelo Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $18.00
7/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
7/8/2025	ARTL Artelo Biosciences	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/8/2025	ARTL Artelo Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$20.00
7/1/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/23/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/11/2025	ARTL Artelo Biosciences	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARTL Artelo Biosciences	N/A	N/A	N/A	N/A	($2.00) per share	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	$0.18 per share	N/A
MURA Mural Oncology	N/A	N/A	N/A	N/A	$3.39 per share	N/A
RNTX Rein Therapeutics	N/A	N/A	$0.50 per share	2.52	$0.13 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARTL Artelo Biosciences	-$9.83M	-$19.05	N/A	N/A	N/A	N/A	-497.68%	-213.76%	11/10/2025 (Estimated)
MDCX Medicus Pharma	-$11.16M	-$1.34	N/A	N/A	N/A	N/A	-549.30%	-228.06%	N/A
MURA Mural Oncology	-$128.51M	-$8.59	N/A	N/A	N/A	N/A	-107.76%	-87.57%	N/A
RNTX Rein Therapeutics	-$62.88M	-$2.69	N/A	N/A	N/A	N/A	-141.11%	-33.83%	N/A

Latest ARTL, MURA, RNTX, and MDCX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	RNTX Rein Therapeutics	-$0.22	-$0.28	-$0.06	-$0.28	N/A	N/A
8/13/2025	Q2 2025	ARTL Artelo Biosciences	-$0.13	-$5.61	-$5.48	-$5.61	N/A	N/A
8/11/2025	Q2 2025	MDCX Medicus Pharma	-$0.39	-$0.43	-$0.04	-$0.43	N/A	N/A
8/4/2025	Q2 2025	MURA Mural Oncology	-$1.13	-$1.77	-$0.64	-$2.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARTL Artelo Biosciences	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
MURA Mural Oncology	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARTL Artelo Biosciences	N/A	0.39	0.39
MDCX Medicus Pharma	N/A	1.29	1.29
MURA Mural Oncology	N/A	2.87	2.87
RNTX Rein Therapeutics	N/A	0.86	1.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARTL Artelo Biosciences	0.87%
MDCX Medicus Pharma	N/A
MURA Mural Oncology	80.21%
RNTX Rein Therapeutics	90.89%

Insider Ownership

Company	Insider Ownership
ARTL Artelo Biosciences	5.80%
MDCX Medicus Pharma	11.20%
MURA Mural Oncology	2.20%
RNTX Rein Therapeutics	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARTL Artelo Biosciences	5	704,000	663,000	Not Optionable
MDCX Medicus Pharma	N/A	13.57 million	12.05 million	N/A
MURA Mural Oncology	119	17.32 million	16.94 million	Optionable
RNTX Rein Therapeutics	9	23.31 million	22.12 million	N/A

ARTL, MURA, RNTX, and MDCX Headlines

Recent News About These Companies

Rein Therapeutics (NASDAQ:RNTX) Cut to "Hold" at Brookline Capital Management

August 21 at 2:29 AM | americanbankingnews.com

Brookline Capital Downgrades Rein Therapeutics (RNTX)

August 19, 2025 | msn.com

Rein announces U.K. MHRA authorized to initiate Phase 2 ‘RENEW’ trial

August 19, 2025 | msn.com

Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

August 19, 2025 | globenewswire.com

Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025

August 14, 2025 | globenewswire.com

XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration

August 7, 2025 | finance.yahoo.com

Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing

July 30, 2025 | finance.yahoo.com

RNTX - Rein Therapeutics Inc Dividends - Morningstar

June 26, 2025 | morningstar.comM

Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

June 24, 2025 | prnewswire.com

US FDA puts on hold Rein Therapeutics' lung disease drug trial

June 12, 2025 | reuters.com

RNTX Rein Therapeutics Inc.

June 1, 2025 | seekingalpha.com

Rein Therapeutics, Inc.: Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 27, 2025 | finanznachrichten.de

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 27, 2025 | prnewswire.com

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

May 19, 2025 | prnewswire.com

Rein Therapeutics, Inc.: Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 16, 2025 | finanznachrichten.de

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025 | prnewswire.com

Rein Therapeutics begins trial for idiopathic pulmonary fibrosis treatment

May 13, 2025 | msn.com

Rein Therapeutics, Inc.: Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 12, 2025 | finanznachrichten.de

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 12, 2025 | prnewswire.com

Rein Therapeutics to integrate Qureight’s platform in trial of IPF treatment

May 2, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTL, MURA, RNTX, and MDCX Company Descriptions

Artelo Biosciences NASDAQ:ARTL

$9.35 -0.18 (-1.89%)

Closing price 08/22/2025 03:56 PM Eastern

Extended Trading

$9.48 +0.14 (+1.44%)

As of 08/22/2025 07:00 PM Eastern

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Medicus Pharma NASDAQ:MDCX

$2.22 -0.23 (-9.39%)

As of 08/22/2025 04:00 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

Mural Oncology NASDAQ:MURA

$2.08 +0.01 (+0.48%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.07 -0.01 (-0.48%)

As of 08/22/2025 07:26 PM Eastern

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.

Rein Therapeutics NASDAQ:RNTX

$1.27 +0.14 (+12.39%)

As of 08/22/2025 03:59 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time